such as corticosteroids, for 24 weeks. All patients had chronic or persistent ITP; at screening, all had received at least 2 prior ITP therapies or 1 prior and 1 concurrent treatment
17 In May 2022, the European Commission granted conditional marketing authorization of CARVYKTI® (cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma who have received at least three prior therapi...
kimiashadkami/javaparserPublic forked fromjavaparser/javaparser NotificationsYou must be signed in to change notification settings Fork0 Star0 Files master .github .mvn dev-files doc javaparser-core-generators javaparser-core-metamodel-generator ...